The HPV Vaccine Is Only One Piece of the Puzzle, India’s Strategy to Eliminate Cervical Cancer
On February 28, 2026, India embarked on a historic public health initiative. The nationwide rollout of the human papillomavirus (HPV) vaccine began, joining the country to a group of 148 nations that have implemented HPV vaccination programmes. For the first three months, the campaign will operate in an intensive “campaign mode,” voluntarily vaccinating all girls aged 14. After this initial phase, the vaccine will be made available at all government health centres free of cost. It is a moment of immense promise, a significant stride towards protecting the next generation of Indian women from a devastating disease. But as Dr. Kinshuk Gupta argues in a sobering analysis, the vaccine, while essential, is only one piece of a much larger and more complex puzzle. Without a comprehensive strategy that addresses screening, education, and deeply entrenched social and cultural barriers, India risks missing the opportunity to eliminate cervical cancer.
The statistics are stark and demand urgent action. Cervical cancer is the fourth most common cancer among women globally. In India, it is the second most common, a position it has held for far too long. The numbers are brutal in their arithmetic: a new case of invasive cervical cancer surfaces every four minutes in this country, and a woman dies from it every seven minutes. These are not just statistics; they are mothers, daughters, sisters, and wives, whose lives are cut short by a disease that is largely preventable. While several risk factors contribute to cervical cancer—including early age of sexual activity, multiple sexual partners, smoking, a weakened immune system, and poor hygiene—the primary culprit is infection with high-risk strains of the human papillomavirus (HPV). HPV is associated with nearly 70% of all cervical cancer cases. Of the over 100 known strains of the virus, 14 are implicated in causing cancer.
The vaccine being rolled out in India is Gardasil 4. It protects against four strains of HPV: the two most common high-risk types, 16 and 18, which are responsible for the majority of cervical cancers, as well as types 6 and 11, which cause genital warts. This is a powerful tool. But even as the vaccine is welcomed, experts remain divided on several critical questions, and public health officials must be prepared to address them.
The first major concern is the duration of protection. The vaccination is being administered to girls between the ages of 9 and 14. This is the optimal window for vaccination, as it is before most individuals become sexually active. However, the peak incidence of cervical cancer occurs much later in life, typically between the ages of 50 and 59. This creates a gap of four to five decades between vaccination and the period of highest risk. The question that naturally arises is: does the protection last that long? India has opted for a one-dose regimen, which recent studies suggest has comparable efficacy to the traditional two or three-dose schedules. This is a cost-effective and logistically simpler approach. But doubts remain about the potential need for booster doses later in life. Long-term, rigorous follow-up studies will be essential to document the duration of protection beyond the initial post-vaccination period. The absence of this data should not delay the rollout, but it should inform a strategy of continued monitoring and research.
The second, and perhaps more formidable, challenge lies in overcoming social and cultural myths and misinformation. Studies have consistently shown that knowledge about HPV, its link to cervical cancer, and the availability of a vaccine remains dangerously low, particularly among beneficiaries in rural areas and those belonging to lower socioeconomic groups. Even in communities where awareness is relatively higher, this knowledge does not always translate into a change in attitude or practice. The decision to vaccinate a daughter is mediated by a complex web of parental beliefs, perceived risks, and social norms. In a society where open discussion about sexually transmitted infections is often taboo, introducing a vaccine against a virus that is sexually transmitted requires a delicate and culturally sensitive approach.
This is where education and community engagement must become integral to the vaccination strategy. The vaccine cannot be rolled out in a vacuum. It must be accompanied by a parallel, sustained campaign of public awareness. School health initiatives can serve as a critical platform for delivering age-appropriate information about HPV, vaccination, and cancer, not only to adolescents but also to their guardians, teachers, and communities. Integrating awareness into existing adolescent health programmes, such as the Rashtriya Kishor Swasthya Karyakram (RKSK), can help ensure that education precedes misinformation, and that the vaccine is accepted not with fear, but with understanding. Research has shown that maternal education, the perception of disease severity, and the expressed intention of parents are among the strongest predictors of vaccine uptake. Empowering mothers with accurate information is, therefore, one of the most effective interventions we can undertake.
The third, and most critical, piece of the puzzle is screening. Vaccination prevents future infections. But it does nothing for the millions of women who are already adults, who may already have been exposed to the virus, and who are at risk of developing cervical cancer today. For them, the only defence is regular screening. India has, for decades, had screening programmes in place, using methods like the Pap smear and Visual Inspection with Acetic Acid (VIA). The uptake of these screenings, however, has remained abysmally low. The reasons are manifold: lack of awareness, lack of access, embarrassment, and the perceived cost and inconvenience. A woman may not think to get screened until she has symptoms, and by then, it is often too late.
Newer, more patient-friendly technologies offer a glimmer of hope. Self-sampling for HPV testing has emerged as a promising alternative. A woman can collect her own sample in the privacy of her home and send it to a lab for analysis. This bypasses many of the cultural and logistical barriers that prevent women from accessing traditional screening. However, the high cost of these tests currently limits their widespread use. Bringing down the cost and integrating self-sampling into the public health system should be a top priority.
The World Health Organization has set an ambitious target for the elimination of cervical cancer by 2030, encapsulated in its 90-70-90 goals: 90% of girls fully vaccinated against HPV by age 15; 70% of women screened with a high-precision test by age 35 and again by age 45; and 90% of women identified with cervical disease receiving treatment and care. India’s vaccine rollout is a massive step towards the first goal. But achieving the second and third goals will require an even greater effort. It will require building a robust screening infrastructure, training healthcare workers, and creating a culture where regular screening is as normal and accepted as vaccinating a child. It will require ensuring that every woman who tests positive has access to affordable, quality treatment.
The HPV vaccine is a historic and essential tool. But it is not a magic bullet. It is one piece of a large and complex puzzle. The full potential of this vaccine will only be realized if it is complemented by a comprehensive strategy that includes sustained public education, aggressive community engagement, accessible and affordable screening for all women, and a robust treatment pipeline. The vaccine offers a chance to protect the next generation. But we must not forget the women of this generation. Their lives depend on the other pieces of the puzzle being put in place just as carefully, just as urgently, and just as thoughtfully.
Questions and Answers
Q1: What is the scale of the cervical cancer problem in India, and what is its primary cause?
A1: Cervical cancer is the second-most common cancer among women in India. A new case occurs every four minutes, and a woman dies from it every seven minutes. While several risk factors exist, infection with high-risk strains of the Human Papillomavirus (HPV) is associated with nearly 70% of all cervical cancer cases.
Q2: What are the main concerns raised by experts regarding the HPV vaccine rollout in India?
A2: Experts have two main concerns:
-
Duration of protection: The vaccine is given to girls aged 9-14, but cervical cancer peaks at ages 50-59. With India using a one-dose regimen, doubts remain about whether protection will last for four decades and whether booster doses will eventually be needed.
-
Social and cultural myths: Awareness about HPV and the vaccine is low, especially in rural areas. Overcoming taboos around discussing a sexually transmitted infection and convincing parents to vaccinate their daughters requires a major, culturally sensitive education campaign.
Q3: Why is the vaccine alone not enough to eliminate cervical cancer?
A3: The vaccine prevents future HPV infections in young girls. It does nothing for the millions of adult women who may already have been exposed to the virus and are at risk of developing cancer today. For these women, the only defence is regular screening (like Pap smears) and access to treatment.
Q4: What is the current state of cervical cancer screening in India, and what promising alternative exists?
A4: The uptake of traditional screening methods like Pap smears and Visual Inspection with Acetic Acid (VIA) has been “abysmally low” due to lack of awareness, access, and cultural barriers. A promising alternative is self-sampling for HPV testing, which allows women to collect their own sample privately, but its high cost currently limits its widespread use.
Q5: What are the WHO’s 90-70-90 targets for eliminating cervical cancer by 2030?
A5: The WHO’s targets are:
-
90% of girls fully vaccinated against HPV by age 15.
-
70% of women screened with a high-precision test by age 35 and again by age 45.
-
90% of women identified with cervical disease receiving appropriate treatment and care.
India’s vaccine rollout addresses the first target, but massive efforts are still needed on screening and treatment.
